ProCE Banner Activity

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the Netherlands and the United Kingdom (Podcast Pearls)

PDF
Experts from the Netherlands and the United Kingdom provide their thoughts on recent advances with immune checkpoint therapy for advanced urothelial carcinoma

Released: December 10, 2020

Expiration: December 09, 2021

No longer available for credit.

Share

Faculty

Thomas Powles

Thomas Powles, MBBS, MRCP, MD

Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomews Hospital (Barts Health NHS Trust)
London, United Kingdom

Michiel van der Heijden

Michiel van der Heijden, MD, PhD

Medical Oncologist and Research Group Leader
Medical Oncology and Molecular Carcinogenesis
Stichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis
Medical Oncologist
Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer Institute
Amsterdam, Netherlands

Supporters

Supported by an educational grant from

Pfizer and EMD Serono

Faculty Disclosure

Primary Author

Thomas Powles, MBBS, MRCP, MD

Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomews Hospital (Barts Health NHS Trust)
London, United Kingdom

Michiel van der Heijden, MD, PhD

Medical Oncologist and Research Group Leader
Medical Oncology and Molecular Carcinogenesis
Stichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis
Medical Oncologist
Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer Institute
Amsterdam, Netherlands